The tweet was deleted by the author.
But we saved everything 🙂.
REGENXBIO has reiterated its commitment to placing patients and families at the forefront of its initiatives, focusing on the ongoing AFFINITY DUCHENNE study.
Vanessa Jimenez, Associate Director of Clinical Operations at REGENXBIO, explained that the study is structured to offer ongoing support to families navigating Duchenne muscular dystrophy. The company aims to ensure every stage of research and care is attuned to the needs of patients and their loved ones.
REGENXBIO plans to present new clinical trial data for its RGX-202 gene therapy at the upcoming 2026 MDA Clinical and Scientific Conference. The company has also recognized the role of women leadership in driving its mission, recently honoring the expertise and contributions of its women employees on International Women’s Day. These efforts align with the company’s ongoing focus on research and patient engagement.